Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
PsilocinCat. No. 4412 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 4-Hydroxy-N,N-dimethyltryptamine |
Biological Activity
Non-selective serotonin receptor agonist. Active metabolite of psilocybin; hallucinogen.Certificate of Analysis / Safety Data Sheet
References
Merck Index 12 4629.
Almaula et al (1996) Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. Mol.Pharmacol. 50 34. PMID: 8700116.
Lee and Roth (2012) Hallucinogen actions on human brain revealed. Proc.Natl.Acad.Sci.USA 109 1820. PMID: 22308478.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Psilocin, supplier, hallucinogenics, serotonin, serotonergics, 5-ht, receptors, nonselective, agonists
Quick Order
Find multiple products by catalog number
5-HT Review
Written by Nicholas Barnes and John Neumaier, leading experts. Request a copy or view PDF today.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
New Products in this Area
Selective 5-HT7 ligand
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.